aibioPolyPid agrees to $26.7 million in warrant exercises at $3.50 per share
Tickers PYPD
Holders of existing PolyPid warrants will exercise them for $26.7 million at $3.50 per share and receive new warrants at $4.50. The company ties the money to a Phase 3 trial whose effect size its release does not give.
Key facts
- Company
- PolyPid Ltd. (NASDAQ: PYPD)
- News type
- Financings
- Primary source
- PolyPid Ltd. 6-K (2025-06-17)
The warrant exercise
PolyPid Ltd. announced on June 16, 2025 that it had entered into new agreements with certain holders of its existing warrants for their immediate exercise. The warrants cover up to an aggregate of 7,626,514 ordinary shares and were originally issued in January 2024 and December 2024. The holders will exercise at $3.50 per share. The company expects aggregate gross proceeds of $26.7 million.
The release is datelined Petach Tikva, Israel, and describes PolyPid as a late-stage biopharma company aiming to improve surgical outcomes. Its ordinary shares trade on Nasdaq under the ticker PYPD.
The new warrants
In return for exercising for cash, PolyPid will issue 7,626,514 new unregistered warrants. The new warrants are exercisable for up to 7,626,514 ordinary shares at $4.50 per share. They are immediately exercisable and run for two years.
If a holder sells any shares acquired from the existing warrants before the new warrants expire, the new warrants for the corresponding number of shares terminate automatically and are forfeited, unless they are exercised at the same time. A holder who sells therefore gives up the second tranche of coverage for those shares.
The new warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered. PolyPid agreed to file a registration statement covering resale of the shares issuable on their exercise. The release does not say when that filing would be made.
The release gives no figure for cash from a later exercise of the new warrants and no basis for predicting one. The structure means the same 7,626,514 shares could be bought again at a higher price later.
Use of proceeds and runway
PolyPid says the additional funding would extend its runway beyond the anticipated approval of D-PLEX 100 by the U.S. Food and Drug Administration. That approval has not been granted. The company intends to use the net proceeds for its new drug application submission, launch preparations, working capital and general corporate purposes. The application has not yet been submitted.
The release gives no cash balance, net loss or operating cash use. The runway claim is the company's own. The transaction was expected to close on or about June 18, 2025, subject to customary closing conditions.
The release names no placement agent, underwriter or financial advisor for the warrant exercise. It lists LifeSci Advisors only as the company's investor relations contact. It names no legal counsel for either side.
The trial behind the deal
The release ties the exercise to SHIELD II, a Phase 3 trial of D-PLEX 100. PolyPid says the topline results showed a statistically significant reduction in surgical site infections in patients undergoing elective colorectal surgery, and that the trial met its primary endpoint and all key secondary endpoints.
The release does not report the size of that reduction, the number of patients, the comparator arm or a confidence interval. Each is needed to judge how large the benefit is. The word "successful" is the company's own characterization of topline results, and no full data set accompanies the release.
D-PLEX 100 releases doxycycline locally over 30 days to prevent surgical site infections. The release says it has received Breakthrough Therapy designation for that use in elective colorectal surgery. Breakthrough designation is not approval.
What the annual report warns about
PolyPid's Form 20-F, filed February 26, 2025, says the company is heavily dependent on the success of D-PLEX 100. It warns that regulatory approval processes are lengthy, costly and unpredictable, and that it may be difficult to sell product candidates profitably if government coverage and reimbursement are limited. The release does not address those risks.
What comes next
The steps the release names are the close of the exercise around June 18, a resale registration statement, the new drug application and the FDA review. The release gives no date for the submission or the decision. Holders of the $4.50 warrants will decide on exercise on their own timing, so the cash plan depends on steps the filing does not date.